|1.||Kim, Jae-Hun: 2 articles (11/2012 - 09/2011)|
|2.||Yang, Jehoon: 2 articles (11/2012 - 09/2011)|
|3.||Park, Shi-Young: 2 articles (06/2008 - 10/2006)|
|4.||Yi, Kyu-Yang: 2 articles (06/2008 - 10/2006)|
|5.||Kim, Yung-Jin: 2 articles (06/2008 - 10/2006)|
|6.||Song, Hyun Seok: 2 articles (06/2008 - 10/2006)|
|7.||Cha, Ji Hoon: 1 article (11/2012)|
|8.||Kim, Sun I: 1 article (11/2012)|
|9.||Chung, Julius Juhyun: 1 article (11/2012)|
|10.||Yoon, Jaemoon: 1 article (11/2012)|
08/01/2012 - "Evaluation of the angiogenesis inhibitor KR-31831 in SKOV-3 tumor-bearing mice using (64)Cu-DOTA-VEGF(121) and microPET."
06/01/2008 - "These results suggest that KR-31831 may have inhibitory effects on tumor angiogenesis through down-regulation of KDR expression."
10/31/2006 - "Taken together, these results suggest that KR-31831 acts as a novel angiogenesis inhibitor and might be useful for treating hypervascularized cancers."
08/01/2012 - "KR-31831 ((2R,3R,4S)-6-amino-4-[N-(4-chloropheyl)-N-(1H-imidazol-2ylmethyl)amino]-3-hydroxyl-2-methyl-2-dimethoxymethyl-3,4-dihydro-2H-1-benzopyran), an angiogenesis inhibitor, was evaluated in tumor-bearing mice using molecular imaging technology. "
05/01/2012 - "We attempt to determine the effect and mechanism of KR-31831 in rat models of corneal neovascularization and choroidal neovascularization (CNV). "
05/01/2012 - "In the silver nitrate cauterized rat, topical KR-31831 (P = 0.008) or bevacizumab (P = 0.008) reduced effectively the area of corneal neovascularization compared to control on day 14. "
09/01/2011 - "Our results suggest that DCE-MRI can be a useful tool by which to evaluate the anti-angiogenic effect of KR-31831 on a xenografted human ovarian carcinoma model."
09/01/2011 - "The purpose of this research was to investigate the anti-angiogenic inhibitory effect of KR-31831, a newly developed anti-angiogenic agent, on an in vivo human ovarian carcinoma model using dynamic contrast-enhanced (DCE) MRI. "
09/01/2011 - "Evaluation of antiangiogenic effects of a new synthetic candidate drug KR-31831 on xenografted ovarian carcinoma using dynamic contrast enhanced MRI."
|5.||Body Weight (Weight, Body)
|3.||Ethanol (Ethyl Alcohol)